Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Prostate Cancer
Phi Index Can Select Patients with Prostate Cancer for Active Surveillance
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
San Francisco, CA—A new tool called the Prostate Health Index (phi) can identify which patients with favorable-risk prostate cancer can safely be managed with active surveillance and which patients will probably require treatment. The
phi
index is relatively low tech and is calculated using 3 serum measurements: prostate-specific antigen (PSA), free/total PSA, and a measurement called [-2]proPSA.
Read Article
14 New Genetic Markers Predict Risk for Prostate Cancer
By
Neil Canavan
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
A mutation in any 1 of a suite of DNA repair pathway genes may predict not only the risk for familial prostate cancer, but also indicate the presence of a particular aggressive form of the disease, according to results of a new UK study from the Institute of Cancer Research in London.
Read Article
Encouraging Long-Term Safety Data for Radium-223
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
Results of a study reported at the 2014 Genitourinary Cancers Symposium showed that at 1.5 years after the last injection of this therapy, minimal myelosuppression and minimal nonhematologic adverse events were reported, and there were no reports of cancers of concern, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and primary bone cancer
Read Article
QOL Improved with 18 versus 36 Months of Hormonal Therapy in Patients with High-Risk Prostate Cancer, Confirming Earlier Efficacy Evidence
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
San Francisco, CA—Longer-term follow-up of a large randomized phase 3 trial suggests that quality of life (QOL) is improved when patients with high-risk prostate cancer have a shorter versus longer course of androgen- deprivation therapy (ADT) plus radiotherapy as primary treatment. In this follow-up study, 18 months of ADT were found to improve QOL versus 36 months of ADT when added to radiotherapy.
Read Article
Previous Docetaxel Therapy Thwarts Enzalutamide Activity in CRPC
By
Charles Bankhead
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
San Francisco, CA—Men with castration-resistant prostate cancer (CRPC) had inferior time duration to prostate-specific antigen (PSA) progression and of progression-free survival (PFS) if they received the androgen receptor agonist enzalutamide (Xtandi) after the taxane docetaxel (Taxotere) rather than before, according to data from a retrospective study presented at the 2014 Genitourinary Cancers Symposium.
Read Article
FDG-PET Helps Predict Prostate Cancer Prognosis
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
October 2013, Vol 4, No 8
Niagara Falls, Ontario—Researchers have determined that 18F-fluorodeoxyglucose (FDG) positron emission tomography (FDG-PET), a widely available and relatively inexpensive imaging modality, could be used to shape treatment plans for patients who have been diagnosed with high Gleason score prostate cancer.
Read Article
Number of Metabolic Syndrome Risk Factors Influences Risk for Prostate Cancer
By
Rosemary Frei, MSc
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Niagara Falls, Ontario—Previous studies have shown an association between metabolic syndrome and prostate cancer. A study presented at the 2013 Canadian Urological Association annual meeting during a poster presentation investigated the level of prostate cancer risk in relation to the number of risk factors of metabolic syndrome and prostate cancer grade.
Read Article
MR-Guided Laser Ablation of Prostate Cancer Producing Promising Results
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Niagara Falls, Ontario—Magnetic resonance (MR) imaging or MR-guided laser focal therapy for ablating low- to intermediate-risk prostate tumors is showing promise in the hands of a Toronto team, despite a relatively high failure rate.
Read Article
New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Chicago, IL—The rate of therapy for localized prostate cancer does not increase in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy (IMRT), according to an examination of trends using the Surveillance, Epidemiology and End Results (SEER)-Medicare–linked database, according to a poster presentation at the 2013 American Society of Clinical Oncology meeting by lead investigator Florian Rudolf Schroeck, MD, MS, Clinical Lecturer, Urology, University of Michigan, Ann Arbor.
Read Article
Prostatic Inflammation Protects Against Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
July 2013, Vol 4, No 6
Niagara Falls, Ontario—New data presented at the 2013 Canadian Urological Association annual meeting suggest that prostatic inflammation can reduce the risk for developing prostate cancer.
Read Article
Page 6 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma